Beam Therapeutics Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2025: USD 31.69 M

Beam Therapeutics Inc. Depreciation And Amortization is USD 31.69 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 52.39% change year over year. Depreciation and amortization are expense that reduces the value of tangible and intangible assets over their useful lives for tax and reporting purposes.
  • Beam Therapeutics Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 20.80 M, a 34.32% change year over year.
  • Beam Therapeutics Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 15.48 M, a 65.32% change year over year.
  • Beam Therapeutics Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 9.37 M, a 86.07% change year over year.
  • Beam Therapeutics Inc. Depreciation And Amortization for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 5.03 M, a 30.12% change year over year.
Key Data
Date Depreciation And Amortization Dividends Paid Common Stock Issued Common Stock Repurchased